Giancarlo Castaman
University of Florence
435 Papers
3.6K Citations
Giancarlo Castaman is an academic researcher from University of Florence. The author has contributed to research in topics: Medicine & Von Willebrand disease. The author has an hindex of 60, co-authored 389 publications. Previous affiliations of Giancarlo Castaman include UniFi & University of Milan.
Chat about Author
Papers
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII
Davide Matino,Marco Gargaro,Elena Santagostino,Matteo Nicola Dario Di Minno,Giancarlo Castaman,Massimo Morfini,Angiola Rocino,Maria Elisa Mancuso,Giovanni Di Minno,Antonio Coppola,Vincenzo Nicola Talesa,Claudia Volpi,Carmine Vacca,Ciriana Orabona,Rossana G. Iannitti,Maria Gabriella Mazzucconi,Cristina Santoro,Antonella Tosti,Sara Chiappalupi,Guglielmo Sorci,Giuseppe Tagariello,Donata Belvini,Paolo Radossi,Raffaele Landolfi,Dietmar Fuchs,Louis Boon,Matteo Pirro,Emanuela Marchesini,Ursula Grohmann,Paolo Puccetti,Alfonso Iorio,Francesca Fallarino +31 more
TL;DR: The association between IDO1 competence and inhibitor status is investigated by evaluating hemophilia A patients harboring F8-null mutations and it is determined that defective TLR9-mediated activation of IDO 1 induction is associated with an inhibitor-positive status.
Association of factor V deficiency with factor V HR2
TL;DR: Double heterozygosity for HR2 and a factor V defect, including factor V deficiency, increased the thrombotic risk afforded by HR2.
Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia
Marco Ruggeri,Heinz Gisslinger,Alberto Tosetto,C. Rintelen,Christine Mannhalter,Ingrid Pabinger,Navide Heis,Giancarlo Castaman,Edoardo Missiaglia,Klaus Lechner,Francesco Rodeghiero +10 more
TL;DR: The prevalence of the FV Leiden mutation in patients with PV and ET is comparable with that observed in the general population, indicating that screening for FVLeiden may be considered to identify PV andET patients at higher risk of recurrences.
Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia
Eros Di Bona,Giuseppe Avvisati,Giancarlo Castaman,M. L. Vegna,Vitaliana De Sanctis,Francesco Rodeghiero,Franco Mandelli +6 more
TL;DR: A total of 622 consecutive patients with acute promyelocytic leukaemia treated within the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA) group during 1989–97 have been reviewed to assess the clinical effectiveness of all‐trans retinoic acid (ATRA) on the incidence of early haemorrhagic deaths and on APL‐associated coagulopathy.
How I treat von Willebrand disease.
TL;DR: The aim of treatment is to correct either the abnormal/reduced von Willebrand factor and the associated deficiency of factor VIII, when present, and desmopressin is able to transiently correct the deficiency of FVIII and VWF.